Nanoparticle-Mediated Angiotensin-(1-9) Drug Delivery for the Treatment of Cardiac Hypertrophy

dc.catalogadoryvc
dc.contributor.authorSepúlveda-Rivas, Sabrina
dc.contributor.authorLeal, Matías S.
dc.contributor.authorPedrozo, Zully
dc.contributor.authorKogan Alterman, Marcelo
dc.contributor.authorOcaranza Jeraldino, María Paz
dc.contributor.authorMorales, Javier
dc.date.accessioned2024-06-06T19:19:43Z
dc.date.available2024-06-06T19:19:43Z
dc.date.issued2021
dc.description.abstractAng-(1-9) peptide is a bioactive vasodilator peptide that prevents cardiomyocyte hypertrophy in vitro and in vivo as well as lowers blood pressure and pathological cardiovascular remodeling; however, it has a reduced half-life in circulation, requiring a suitable carrier for its delivery. In this work, hybrid nanoparticles composed of polymeric nanoparticles (pNPs) based on Eudragit® E/Alginate (EE/Alg), and gold nanospheres (AuNS), were developed to evaluate their encapsulation capacity and release of Ang-(1-9) under different experimental conditions. Hybrid pNPs were characterized by dynamic light scattering, zeta potential, transmission and scanning electron microscopy, size distribution, and concentration by nanoparticle tracking analysis. Nanometric pNPs, with good polydispersity index and colloidally stable, produced high association efficiency of Ang-(1-9) and controlled release. Finally, the treatment of neonatal cardiomyocytes in culture with EE/Alg/AuNS 2% + Ang-(1-9) 20% pNPs decreased the area and perimeter, demonstrating efficacy in preventing norepinephrine-induced cardiomyocyte hypertrophy. On the other hand, the incorporation of AuNS did not cause negative effects either on the cytotoxicity or on the association capacity of Ang-(1-9), suggesting that the hybrid carrier EE/Alg/AuNS pNPs could be used for the delivery of Ang-(1-9) in the treatment of cardiovascular hypertrophy.
dc.fuente.origenORCID
dc.identifier.doi10.3390/pharmaceutics13060822
dc.identifier.urihttp://dx.doi.org/10.3390/pharmaceutics13060822
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/86559
dc.information.autorucFacultad de Agronomía e Ingenieria Forestal;Kogan Alterman Marcelo;S/I;98569
dc.information.autorucEscuela de Medicina; Ocaranza Jeraldino, María Paz; 0000-0002-4915-6378; 1001254
dc.language.isoen
dc.nota.accesocontenido completo
dc.rightsacceso abierto
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleNanoparticle-Mediated Angiotensin-(1-9) Drug Delivery for the Treatment of Cardiac Hypertrophy
dc.typeartículo
sipa.codpersvinculados1001254
sipa.trazabilidadORCID;2024-06-03
Files